Vaccination Against Hepatitis B and C: Towards Therapeutic Application

REFERENCES

• Huang K., Lin S. Nationwide vaccination: A success story in Taiwan. Vaccine 2000; 18(Suppl 1)S35–38
   Google Scholar
• Penna A., Del Prete G., Cavalli A., Bertoletti A., D'Elios M. M., Sorrentino R., D'Amato M., Boni C., Pilli M., Fiaccadori F., Ferrari C. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25: 1022–1027
   PubMed Web of Science ®Google Scholar
• Webster G. J., Reignat S., Brown D., Ogg G. S., Jones L., Seneviratne S. L., Williams R., Dusheiko G., Bertoletti A. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: Implications for immunotherapy. J Virol 2004; 78: 5707–5719
   PubMed Web of Science ®Google Scholar
• Shoukry N. H., Cawthon A. G., Walker C. M. Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 2004; 58: 391–424
   Google Scholar
• Wertheimer A. M., Miner C., Lewinsohn D. M., Sasaki A. W., Kaufman E., Rosen H. R. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003; 37: 577–589
   PubMedGoogle Scholar
• Racanelli V., Manigold T. Presentation of HCV antigens to naive CD8+T cells: Why the where, when, what, and how are important for virus control and infection outcome. Clin Immunol 2007; 124: 5–12
   PubMed Web of Science ®Google Scholar
• Martin P. I. G. Hepatitis C vaccines. Drug Discov Today: Therap Strategies 2006; 3: 203–209
   Google Scholar
• Elmowalid G. A., Qiao M., Jeong S. H., Borg B. B., Baumert T. F., Sapp R. K., Hu Z., Murthy K., Liang T. J. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci USA 2007; 104: 8427–8432
   PubMed Web of Science ®Google Scholar
• Folgori A., Capone S., Ruggeri L., Meola A., Sporeno E., Ercole B. B., Pezzanera M., Tafi R., Arcuri M., Fattori E., Lahm A., Luzzago A., Vitelli A., Colloca S., Cortese R., Nicosia A. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12: 190–197
   PubMed Web of Science ®Google Scholar
• Fournillier A., Gerossier E., Evlashev A., Schmitt D., Simon B., Chatel L., Martin P., Silvestre N., Balloul J. M., Barry R., Inchauspe G. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long-lasting, and in vivo cross-reactive T cell responses. Vaccine 2007; 25: 7339–7653
   PubMedGoogle Scholar
• Simon B. E., Cornell K. A., Clark T. R., Chou S., Rosen H. R., Barry R. A. DNA vaccination protects mice against challenge with Listeria monocytogenes expressing the hepatitis C virus NS3 protein. Infect Immun 2003; 71: 6372–6380
   Google Scholar
• Menne S., Cote P. J. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 2007; 13: 104–124
   PubMed Web of Science ®Google Scholar
• Polakos N. K., Drane D., Cox J., Ng P., Selby M. J., Chien D., O'Hagan D. T., Houghton M., Paliard X. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol 2001; 166: 3589–3598
   PubMed Web of Science ®Google Scholar
• Gomez C. E., Najera J. L., Krupa M., Esteban M. The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer. Curr Gene Ther 2008; 8: 97–120
   PubMed Web of Science ®Google Scholar
• Vandepapeliere P., Lau G. K., Leroux-Roels G., Horsmans Y., Gane E., Tawandee T., Merican M. I., Win K. M., Trepo C., Cooksley G., Wettendorff M., Ferrari C. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: A randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 2007; 25: 8585–8597
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M., Fontaine H., Brechot C., Pol S., Michel M. L. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine 2006; 24: 4482–4489
   PubMed Web of Science ®Google Scholar
• Yang S. H., Lee C. G., Park S. H., Im S. J., Kim Y. M., Son J. M., Wang J. S., Yoon S. K., Song M. K., Ambrozaitis A., Kharchenko N., Yun Y. D., Kim C. M., Kim C. Y., Lee S. H., Kim B. M., Kim W. B., Sung Y. C. Correlation of antiviral T-cell responses with suppression of viral rebound in chronic hepatitis B carriers: A proof-of-concept study. Gene Ther 2006; 13: 1110–1117
   PubMed Web of Science ®Google Scholar
• Betts M. R., Nason M. C., West S. M., De Rosa S. C., Migueles S. A., Abraham J., Lederman M. M., Benito J. M., Goepfert P. A., Connors M., Roederer M., Koup R. A. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781–4789
   PubMed Web of Science ®Google Scholar
• Darrah P. A., Patel D. T., De Luca P. M., Lindsay R. W., Davey D. F., Flynn B. J., Hoff S. T., Andersen P., Reed S. G., Morris S. L., Roederer M., Seder R. A., Multifunctional R. A. TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13: 843–850
   PubMed Web of Science ®Google Scholar
• Ferrari C. Therapeutic vaccination for hepatitis C: Can protective T-cell responses be restored after prolonged antigen exposure?. Gastroenterology 2008; 134: 1601–1604
   Google Scholar